Delic’s Vision Comes Into Focus With a Flurry of Acquisitions

Press Release

Whitefish, Montana – (NewMediaWire) – March 11, 2021 – CFN Enterprises Inc.(OTCQB: CNFN), owner and operator of CFN Media, the leading media network dedicated to the global legal cannabis, CBD and psychedelics industries, today announced an article coveringThe Delic Holdings Inc.(CSE: DELC) (OTCQX: DELCF). Investors have many different options when it comes to building exposure into the psychedelics sector within their portfolios. While some companies are undergoing large-scale and years-long clinical trials to prove efficacy, others are opening wellness clinics or cultivating mushrooms in legal jurisdictions. Delic Holdings Inc.(CSE: DELC) (OTCQB: DELCF) is a relatively new player to the psychedelics public markets space, but its management team has previous deep experience in another highly-regulated industry—cannabis—as former high-level executives at High Times. With its recent flurry of acquisitions, the team’s vision for the future of psychedelics is becoming increasingly clear and compelling to investors and the capital markets. Let’s take a look at some of the recent acquisitions and why investors may want to take note.  Starting a Home Cultivation Movement DELIC recently acquireda legacy counterculture distributor of psychedelic media and creator of one of the first self-contained mushroom grow kits. Before developing and selling tens of thousands of mushroom kits around the world, Homestead Book Company was one of the earliest distributors for High Times and other counterculture publications. The acquisition enables DELIC to increase the products available on Reality Sandwich, which attracts over 200,000 unique visitors each month. In March, the company expects to launch a new mushroom kit that will have a modern interpretation of the company’s storied history and will include everything a consumer needs to become an at-home mycologist. The company’s overarching goal is to become a leader in the home cultivation movement by leveraging a combination of educational content, innovative products and complementary products. With psychedelics limited to clinics at the moment, home cultivation could be a cornerstone of the mindfulness and meditative side of the movement. Click here to receive an investor presentation and corporate updates Building a Network of Ketamine Clinics DELIChas also been targeting the “right-now” clinical side of the psychedelics industry with the acquisitionof Ketamine Infusion Centers LLC last month. With two ketamine infusion treatment clinics in Arizona and California, the company offers ketamine as a mental health treatment for chronic mental health disorders including depression, anxiety, substance abuse, alcoholism, PTSD, and a range of other mental health disorders. Supported by clinical trials and peer reviewed studies, evidence of the efficacy of ketamine infusions is quickly growing. By leveraging its existing media assets and connections, Delic hopes to supercharge the ketamine clinic business and scale up over time. DELIC’s access to the public markets could also support a more rapid expansion of the business, which has been growing quarter by quarter. More recently, the company appointedKyle Snook, former COO of Actify Neurotherapies, to its Board of Advisors. Actify Neurotherapies was a venture-backed startup that was formerly the largest provider of IV Ketamine Therapies nationwide. Combined with an MBA from Harvard Business School, Snook’s experience in the business will be instrumental to DELIC’s growth. Amassing a Psilocybin IPPortfolio to Drive Value  DELIC is equally focused on building shareholder value through the acquisition of intellectual property in the psychedelics space with the acquisitionof Complex Biotech Discovery Ventures (CBDV). In addition to being a profitable business with over 50 cannabis and psychedelics clients, CBDV’s licensed psilocybin and cannabis research lab is well-equipped for the development of IP. The company aims to build out an IP portfolio of psilocybin analogs, novel compounds and deliver mechanisms that could pave the way for future …